Catalyst Pharmaceuticals, Inc. (CPRX)

15,94 +0,29 (+1,85%) Alla chiusura: 04:00PM EDT

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 167

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Richard John Daly M.B.A.	President, CEO & Director	68,12k	N/D	1961
Dr. Steven R. Miller Ph.D.	Executive VP, COO & Chief Scientific Officer	884,7k	N/D	1962
Dr. Gary Ingenito M.D., Ph.D.	Chief Medical & Regulatory Officer	811,39k	N/D	1956
Mr. Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	799,82k	N/D	1971
Mr. Michael W. Kalb CPA	Executive VP, Treasurer & CFO	N/D	N/D	1971
Ms. Mary Coleman	VP & Head of Investor Relations	N/D	N/D	N/D
Mr. Brian Elsbernd J.D.	Chief Compliance Officer & Chief Legal Officer	311,42k	N/D	1964
Mr. Pete Curry Sr.	Vice President of Sales	N/D	N/D	N/D
Dr. Stanley Iyadurai M.D., Ph.D.	Senior Vice President of Medical Affairs & Drug Discovery	N/D	N/D	N/D
Dr. Preethi Sundaram Ph.D.	Chief Strategy Officer	511,25k	N/D	1976

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Governance aziendale

L'ISS Governance QualityScore di Catalyst Pharmaceuticals, Inc. al 1 maggio 2024 è 5. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 6; diritti degli azionisti: 3; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.